We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

MorphoSys Initiates Phase 2/3 B-MIND trial with MOR208 in DLBCL

News   Sep 06, 2016

 
MorphoSys Initiates Phase 2/3 B-MIND trial with MOR208 in DLBCL
 
 
 

RELATED ARTICLES

Loss of Tight Junction Protein Promotes Development of Precancerous Cells

News

Tight junctions are multi-protein complexes that serve as barriers in epithelial tissues such as the skin or lining of the gut. Loss of a specific tight junction barrier protein, claudin 18, occurs in the majority of gastric cancer patients and is correlated with poor prognosis in patients with advanced gastric cancer.

READ MORE

Excess Body Weight Responsible for 4% of Cancers Worldwide

News

Policies, economic systems, and marketing practices that promote the consumption of energy-dense, nutrient-poor food, changing behavioral patterns that couple high total energy intake with insufficient physical activity, and human-built environments that amplify these factors are driving a worldwide rise in excess body weight, according to a new report.

READ MORE

Shortcut to Recreating Key HIV Antibody for Vaccines

News

A portion of the roadmap toward effective neutralization of HIV has been clarified, identifying the steps that a critical HIV antibody takes to develop and maintain its ability to neutralize the virus.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE